<img src="https://s3.amazonaws.com/dl.jddonline.com/articleimages/vol18_6_6/Figure-4.jpg" />
<img src="https://s3.amazonaws.com/dl.jddonline.com/articleimages/vol18_6_6/Figure-5.jpg" />
Patient Satisfaction (PSS) and Quality of Life
There were no significant differences in PSS mean scores at week 12 between tazarotene 0.045% lotion and tazarotene 0.1% cream (P=.372) or combined vehicle (P=.242). Overall, patients treated with tazarotene 0.045% lotion assessed their treatment satisfaction higher than tazarotene 0.1% cream (mean score of 7.7 versus 7.4).
There were also no statistically significant differences in the improvement between treatment groups based on the meanAcne-QoL assessments in each of the 4 evaluated domains. Improvements in self-perception, role-emotional, and role-social were similar with tazarotene 0.045% lotion and tazarotene 0.1% cream, and markedly greater than those achieved in the combined vehicle groups. In terms of acne symptoms improvement, the absolute change from baseline with tazarotene 0.045% lotion was again greater than that achieved with the combined vehicle, however tazarotene 0.1% cream only demonstrated an improvement similar to that achieved with vehicle.